This site uses cookies to bring you the best experience. Find out more
Skip to main content


Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

Contact us on if you would like to know more about any of these stories.

You can also keep up to date by following us on Twitter or LinkedIn    

Oxford Cancer Biomarkers announces European expansion of chemotherapy toxicity test & independent real-world evidence of patient benefit

ToxNav®, a CE-marked in vitro diagnostics product is now registered in the European database on medical devices (EUDAMED).  Independent study publication highlights patient benefits, cost-savings and opportunity for ToxNav® to address potential health inequalities in current approaches to DPYD testing. OXFORD, UK – 26th September 2022 – Oxford Cancer Biomarkers Ltd (OCB) announces that ToxNav®, its proprietary pharmacogenomics test for... Read more

Evox Therapeutics expands its exosome manufacturing patent portfolio

EVOX THERAPEUTICS EXPANDS ITS EXOSOME MANUFACTURING PATENT PORTFOLIO Four newly issued patents cover key purification processes and methods of exogenous loading OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted four new patents covering a broad range of exosome manufacturing methods and... Read more

Digital Catapult unveils five firms to explore potential of Open RAN technology on SONIC Labs testbed

Digital Catapult, with support from its partner Ofcom, has onboarded five companies to its SONIC Labs programme to trial the integration of Open RAN (Radio Access Network) products into working end-to-end systems Participating organisations will work collaboratively with each other, Digital Catapult and Ofcom to integrate and test their products in lab and indoor mobile network settings, accelerating their route to... Read more

Oxford Science Enterprises Raises £250 Million

New funding deepens capital pool available to drive the creation and growth of transformational businesses built on ground-breaking Oxford science Oxford, UK: July 18, 2022 – Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its unique partnership with the University of Oxford, today announces it has raised a further £250 million ($300... Read more


MIROBIO RAISES $97 MILLION SERIES B FINANCING TO DEVELOP CHECKPOINT AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASES Financing led by Medicxi with significant participation from new and existing shareholders Lead program MB272 targeting checkpoint receptor BTLA, entering Phase I clinical trials Funds will be used to advance pipeline of immune checkpoint agonists into clinical trials in autoimmune diseases OXFORD, United Kingdom, June 29... Read more